Pharmaceuticals, Biotechnology and Life Sciences
PITTSBURGH–(BUSINESS WIRE)–ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute…
V114 Met Primary Endpoint by Demonstrating Noninferiority to PCV13 for all Shared Serotypes, and an Immune Response for Two Additional…
ANN ARBOR, Mich.–(BUSINESS WIRE)–Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced…
STONY BROOK, N.Y.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24apdn&src=ctag" target="_blank"gt;$apdnlt;/agt; lt;a href="https://twitter.com/hashtag/anticounterfeiting?src=hash" target="_blank"gt;#anticounterfeitinglt;/agt;–Applied DNA Sciences, Inc. (NASDAQ:APDN), announced today that American & Efird (A&E),…
Genprex takes next steps toward identifying drug name for future commercialization AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX),…
SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ALS?src=hash" target="_blank"gt;#ALSlt;/agt;–Neuropore Therapies, Inc. announced today that it has initiated a Phase 1 clinical trial in healthy…
VIENNA, Va.–(BUSINESS WIRE)–The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders: Dear CEL-SCI Shareholders: The…
LEBANON, N.H.–(BUSINESS WIRE)–Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced…
LEBANON, N.H.–(BUSINESS WIRE)–Adimab, LLC, the leading provider of antibody discovery and optimization technology, today announced the expansion of an earlier…
Sixth pharma partner to internalize the Adimab platform LEBANON, N.H.–(BUSINESS WIRE)–Adimab, LLC, the global leader in the discovery and optimization…